CME: Improving the Treatment and Management of Schizophrenia: An Overview of Current and Novel Approaches
ACCREDITATION EXPIRED: April 29, 2018
Activity Description / Statement of Need:
In this online CME self-learning program:
Schizophrenia, by nature, presents manifold challenges to the healthcare professional directing neuropsychiatric care. Not only do practical matters like medication adherence play a role in the success of therapy, but it behooves clinicians to also have a well-informed understanding of the symptomatology and treatment course of the disease. Atypical antipsychotics are the mainstay of initial pharmacotherapy, with oral agents being preferred first. However, recent literature has questioned whether earlier treatment with long-acting injectable antipsychotics might improve adherence or whether other treatment modalities like behavioral intervention strategies should be stressed. Poor patient adherence to schizophrenia medications is associated with suboptimal clinical outcomes, and improving adherence may enhance quality of life and reduce the risk of hospitalization, thereby potentially lowering health resource utilization and its associated costs.
This program has been designed to bring healthcare professionals’ knowledge up to date with the currently best and recommended practices in treating Schizophrenia.
Agenda:
|
Introduction, Disclosures |
|
Primer on schizophrenia’s epidemiology, neuropathophysiology, presentation, comorbidities, and psychosocial impact
|
|
Updates in schizophrenia treatment and strategies for barriers to care
|
|
Summary, conclusions, and best practice recap |
Target Audience:
Healthcare professionals specializing in: psychiatry, primary care, and those who otherwise commonly care for patients with Shizophrenia or related psychiatric diseases.
This program is supported by an educational grant from Alkermes.
Release Date: April 29, 2016 -- Expiration Date: April 29, 2018
Faculty: Jacob Moussai, MD
Agenda
Learning Objectives
By the end of the session the participant will be able to:
- Describe the pathophysiology of schizophrenia and the role the neurotransmitters play in it.
- Describe the benefits and risks of pharmacotherapy for schizophrenia and take them into account when formulating a treatment plan for different patients.
- Formulate a treatment plan for a variety of patients with schizophrenia.
- Recommend therapy changes in patients who are unable to tolerate a prescribed treatment.
- Identify barriers to care in patients with schizophrenia and develop strategies to abate them.
Accreditation
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Dr. Jacob Moussai, MD has no relevant financial disclosures.
Disclosures of Educational Planners: Charles Turck, PharmD is an officer and part owner of ScientiaCME, LLC with no relevent financial disclosures.
Commercial Support Disclosure: This program is supported by an educational grant from Alkermes.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 0% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
Best Practices and Advances in Treatment Strategies in Bipolar Disorder Pharmacotherapy
Alcohol Use Disorder (AUD): Therapeutic Updates and Best Practices
Schizophrenia: Updates from the American Psychiatric Association Annual Meeting (APA) 2017